NEW YORK, June 28 (GenomeWeb News) - Exagen Diagnostics has raised $7 million in a Series B round of private-equity financing, the company said today.
Tullis-Dickerson led the round, while vSpring Capital and Wasatch Venture Fund participated. As GenomeWeb News has reported, Exagen completed a $5.7 million Series A round in early 2004 with the same group of investors.
Exagen, based in
The company said its first test will be the Key2 Breast Cancer Prognosis panel, which is designed to detect changes in DNA copy number in both hormone receptor-positive and hormone receptor-negative tumors.